Uterine fibroids are benign monoclonal neoplasms of the myometrium, representing the
most common tumors in women worldwide. To date, no long-term or noninvasive treatment …

Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

Understanding tumor microenvironment (TME) reprogramming in gastric adenocarcinoma
(GAC) progression may uncover novel therapeutic targets. Here, we performed single-cell …

Gastric carcinoma (GC) is a complex multifactorial disease occurring as sequential events
commonly referred to as the Correa's cascade, a stepwise progression from non-active or …

Importance Neoadjuvant therapies have been shown to decrease tumor burden, increase
resection rate, and improve the outcomes among patients with locally advanced gastric …

Targetable drivers governing 5-fluorouracil and cisplatin (5FU+ CDDP) resistance remain
elusive due to the paucity of physiologically and therapeutically relevant models. Here, we …

Background The combination of immune checkpoint blockade and chemotherapy has
revolutionized the treatment of advanced gastric cancer (GC). It is crucial to unravel …

The combination of perioperative chemotherapy plus complete surgical resection is currently
accounted as the first-choice strategy in patients with locally advanced Gastric Cancer …

Gastric cancer (GC) is commonly treated by chemotherapy using 5-fluorouracil (5-FU)
derivatives and platinum combination, but predictive biomarker remains lacking. We develop …

Adding anti–programmed cell death protein 1 (anti–PD-1) to 5-fluorouracil (5-FU)/platinum
improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To …